Role of microRNA-21 in cardiovascular diseases

Abstract

Abstract: MicroRNA-21 (miR-21) is abundantly expressed in almost all tissues and involved in many diseases. It is reported recently that expression of miR-21 is changed in many cardiovascular diseases, such as atherosclerosis, pulmonary hypertension, heart failure and myocardial ischemia. MiR-21 also participates in functional regulation of vascular smooth muscle cells, endothelial cells, cardiac myocytes and cardiac fibroblasts. All these effects of miR-21 are mediated by directing at multiple targets. There are increasing evidence suggesting that miR-21 plays a crucial role in cardiovascular diseases and may be a potential therapeutic target.

Key words: MicroRNA, MicroRNA-21, Cardiovascular disease

CLC Number:

WU Wei-hua, HU Chang-ping. Role of microRNA-21 in cardiovascular diseases[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(6): 709-714.

References

[1] He J, Gu D, Wu X, et al. Major causes of death among men and women in China[J]. N Engl J Med, 2005, 353(11):1124-1134.
[2] Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function[J]. Cell, 2004, 116(2):281-297.
[3] Denli AM, Tops BB, Plasterk RH, et al. Processing of primary microRNAs by the Microprocessor complex[J]. Nature, 2004, 432(7014):231-235.
[4] Baek D, Villen J, Shin C, et al. The impact of microRNAs on protein output[J]. Nature, 2008, 455(7209):64-71.
[5] da Costa Martins PA, De Windt LJ. miR-21: a miRaculous Socratic paradox[J]. Cardiovasc Res, 2010, 87(3):397-400.
[6] Kumarswamy R, Volkmann I, Thum T. Regulation and function of miRNA-21 in health and disease[J]. RNA Biol, 2011, 8(5):706-713.
[7] Fujita S, Ito T, Mizutani T, et al. miR-21 Gene expression triggered by AP-1 is sustained through a double-negative feedback mechanism[J]. J Mol Biol, 2008, 378(3):492-504.
[8] Du J, Yang S, An D, et al. BMP-6 inhibits microRNA-21 expression in breast cancer through repressing deltaEF1 and AP-1[J]. Cell Res, 2009, 19(4):487-496.
[9] Choy MK, Movassagh M, Siggens L, et al. High-throughput sequencing identifies STAT3 as the DNA-associated factor for p53-NF-kappaB-complex-dependent gene expression in human heart failure[J]. Genome Med, 2010, 2(6):37.
[10] Loffler D, Brocke-Heidrich K, Pfeifer G, et al. Interleukin-6 dependent survival of multiple myeloma cells involves the Stat3-mediated induction of microRNA-21 through a highly conserved enhancer[J].Blood, 2007, 110(4):1330-1333.
[11] Velu CS, Baktula AM, Grimes HL. Gfi1 regulates miR-21 and miR-196b to control myelopoiesis[J]. Blood, 2009,113(19):4720-4728.
[12] Wickramasinghe NS, Manavalan TT, Dougherty SM, et al. Estradiol downregulates miR-21 expression and increases miR-21 target gene expression in MCF-7 breast cancer cells[J]. Nucleic Acids Res, 2009, 37(8):2584-2595.
[13] Davis BN, Hilyard AC, Lagna G, et al. SMAD proteins control DROSHA-mediated microRNA maturation[J]. Nature, 2008, 454(7200):56-61.
[14] Sahni V, Mukhopadhyay A, Tysseling V, et al. BMPR1a and BMPR1b signaling exert opposing effects on gliosis after spinal cord injury[J]. J Neurosci, 2010, 30(5):1839-1855.
[15] Roy S, Khanna S, Hussain SR, et al. MicroRNA expression in response to murine myocardial infarction: miR-21 regulates fibroblast metalloprotease-2 via phosphatase and tensin homologue[J]. Cardiovasc Res, 2009, 82(1):21-29.
[16] Sayed D, He M, Hong C, et al. MicroRNA-21 is a downstream effector of AKT that mediates its antiapoptotic effects via suppression of Fas ligand[J]. J Biol Chem, 2010, 285(26):20281-20290.
[17] Ji R, Cheng Y, Yue J, et al. MicroRNA expression signature and antisense-mediated depletion reveal an essential role of MicroRNA in vascular neointimal lesion formation[J]. Circ Res, 2007, 100(11):1579-1588.
[18] Lin Y, Liu X, Cheng Y, et al. Involvement of MicroRNAs in hydrogen peroxide-mediated gene regulation and cellular injury response in vascular smooth muscle cells[J]. J Biol Chem, 2009, 284(12):7903-7913.
[19] Cheng Y, Zhu P, Yang J, et al. Ischaemic preconditioning-regulated miR-21 protects heart against ischaemia/reperfusion injury via anti-apoptosis through its target PDCD4[J]. Cardiovasc Res, 2010, 87(3):431-439.
[20] Wang M, Li W, Chang GQ, et al. MicroRNA-21 rgulates vascular smooth muscle cell function via targeting tropomyosin 1 in arteriosclerosis obliterans of lower extremities[J]. Arterioscler Thromb Vasc Biol, 2011, 31(9):2044-2053.
[21] Thum T, Gross C, Fiedler J, et al. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts[J]. Nature, 2008, 456(7224):980-984.
[22] Sayed D, Rane S, Lypowy J, et al. MicroRNA-21 targets Sprouty2 and promotes cellular outgrowths[J]. Mol Biol Cell, 2008, 19(8):3272-3282.
[23] Zhou J, Wang KC, Wu W, et al. MicroRNA-21 targets peroxisome proliferators-activated receptor-{alpha} in an autoregulatory loop to modulate flow-induced endothelial inflammation[J]. Proc Natl Acad Sci U S A, 2011, 108(25):10355-10360.
[24] Cordes KR, Sheehy NT, White MP, et al. miR-145 and miR-143 regulate smooth muscle cell fate and plasticity[J]. Nature, 2009, 29(3):705-710.
[25] Caruso P, MacLean MR, Khanin R, et al. Dynamic changes in lung microRNA profiles during the development of pulmonary hypertension due to chronic hypoxia and monocrotaline[J]. Arterioscler Thromb Vasc Biol, 2010, 30(4):716-723.
[26] Sarkar J, Gou D, Turaka P, et al. MicroRNA-21 plays a role in hypoxia-mediated pulmonary artery smooth muscle cell proliferation and migration[J]. Am J Physiol Lung Cell Mol Physiol, 2010, 299(6):L861-871.
[27] Li T, Cao H, Zhuang J, et al. Identification of miR-130a, miR-27b and miR-210 as serum biomarkers for atherosclerosis obliterans[J]. Clin Chim Acta, 2011,412(1/2):66-70.
[28] Raitoharju E, Lyytikainen LP, Levula M, et al. miR-21, miR-210, miR-34a, and miR-146a/b are up-regulated in human atherosclerotic plaques in the Tampere Vascular Study[J]. Atherosclerosis, 2011, 219(1):211-217.
[29] Fichtlscherer S, De Rosa S, Fox H, et al. Circulating microRNAs in patients with coronary artery disease[J]. Circ Res, 2010, 107(5):677-684.
[30] Cheng Y, Ji R, Yue J, et al. MicroRNAs are aberrantly expressed in hypertrophic heart: do they play a role in cardiac hypertrophy[J] ? Am J Pathol, 2007, 170(6):1831-1840.
[31] Tatsuguchi M, Seok HY, Callis TE, et al. Expression of microRNAs is dynamically regulated during cardiomyocyte hypertrophy[J]. J Mol Cell Cardiol, 2007, 42(6):1137-1141.
[32] Sayed D, Hong C, Chen IY, et al. MicroRNAs play an essential role in the development of cardiac hypertrophy[J]. Circ Res, 2007, 100(3):416-424.
[33] van Rooij E, Sutherland LB, Liu N, et al. A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure[J]. Proc Natl Acad Sci U S A, 2006 103(48):18255-18260.
[34] Carrillo ED, Escobar Y, Gonzalez G, et al. Posttranscriptional regulation of the β₂ subunit of cardiac L-type Ca²⁺ channels by microRNAs during long-term exposure to isoproterenol in rats[J]. J Cardiovasc Pharmacol, 2011, 58(5):470-478.
[35] Patrick DM, Montgomery RL, Qi X, et al. Stress-dependent cardiac remodeling occurs in the absence of microRNA-21 in mice[J]. J Clin Invest, 2010, 120(11):3912-3916.
[36] van Rooij E, Sutherland LB, Thatcher JE, et al. Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis[J]. Proc Natl Acad Sci U S A, 2008, 105(35):13027-13032.
[37] Dong S, Cheng Y, Yang J, et al. MicroRNA expression signature and the role of microRNA-21 in the early phase of acute myocardial infarction[J]. J Biol Chem, 2009, 284(43):29514-29525.
[38] Ren XP, Wu J, Wang X, et al. MicroRNA-320 is involved in the regulation of cardiac ischemia/reperfusion injury by targeting heat-shock protein 20[J]. Circulation, 2009, 119(17):2357-2366.
[39] Yin C, Wang X, Kukreja RC. Endogenous microRNAs induced by heat-shock reduce myocardial infarction following ischemia-reperfusion in mice[J]. FEBS Lett, 2008, 582(30):4137-4142.
[40] Mukhopadhyay P, Mukherjee S, Ahsan K, et al. Restoration of altered microRNA expression in the ischemic heart with resveratrol[J]. PLoS One, 2010, 5(12):e15705.
[41] Yin C, Salloum FN, Kukreja RC. A novel role of microRNA in late preconditioning: upregulation of endothelial nitric oxide synthase and heat shock protein 70[J]. Circ Res, 2009, 104(5):572-575.
[42] Kotlo KU, Hesabi B, Danziger RS. Implication of microRNAs in atrial natriuretic peptide-and nitric oxide signaling in vascular smooth muscle cells[J]. Am J Physiol Cell Physiol, 2011, 301(4):C929-937.
[43] Ikeda S, Kong SW, Lu J, et al. Altered microRNA expression in human heart disease[J]. Physiol Genomics, 2007, 31(3):367-373.
[44] Corsten MF, Dennert R, Jochems S, et al. Circulating MicroRNA-208b and MicroRNA-499 reflect myocardial damage in cardiovascular disease[J]. Circ Cardiovasc Genet, 2010, 3(6):499-506.
[45] Thum T, Galuppo P, Wolf C, et al. MicroRNAs in the human heart: a clue to fetal gene reprogramming in heart failure[J]. Circulation, 2007,116(3):258-267.
[46] Cheng Y, Liu X, Zhang S, et al. MicroRNA-21 protects against the H(2)O(2)-induced injury on cardiac myocytes via its target gene PDCD4[J]. J Mol Cell Cardiol, 2009, 47(1):5-14.
[47] Wu C, So J, Davis-Dusenbery BN, et al. Hypoxia potentiates microRNA-mediated gene silencing through posttranslational modification of Argonaute2[J]. Mol Cell Biol, 2011, 31(23):4760-4774.
[48] von der Thusen JH, van Vlijmen BJ, Hoeben RC, et al. Induction of atherosclerotic plaque rupture in apolipoprotein E-/- mice after adenovirus-mediated transfer of p53[J]. Circulation, 2002, 105(17):2064-2070.
[49] Sano M, Minamino T, Toko H, et al. p53-induced inhibition of Hif-1 causes cardiac dysfunction during pressure overload[J]. Nature, 2007, 446(7134):444-448.
[50] van der Heiden K, Cuhlmann S, Luong le A, et al. Role of nuclear factor kappaB in cardiovascular health and disease[J]. Clin Sci (Lond), 2010, 118(10):593-605.